Klaus Breiner
Directeur/Membre du Conseil chez Orthocon, Inc.
Profil
Klaus Breiner is currently a Director at Orthocon, Inc., Natural Dental Implants AG, Tridek-One Therapeutics SAS, Vico Therapeutics BV, and a Member-Supervisory Board at AM-Pharma Holding BV.
He is also a Managing Partner at Pureos Partners AG since 2017.
Previously, he held positions as an Executive Chairman at Vaximm AG, Director at Agendia NV, Roche Glycart AG, Cervelo Pharmaceuticals Ltd., and a Member-Supervisory Board at AM-Pharma BV.
Dr. Breiner obtained a doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1998, a graduate degree from The University of North Carolina at Charlotte in 1995, and an undergraduate degree from the University of Hagen in 1994.
Postes actifs de Klaus Breiner
| Sociétés | Poste | Début |
|---|---|---|
Bellevue Asset Management (Venture Capital)
 Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Private Equity Investor | 01/01/2004 |
Orthocon, Inc.
 Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Directeur/Membre du Conseil | 01/01/2006 |
Natural Dental Implants AG
 Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | - |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Directeur/Membre du Conseil | - |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Private Equity Investor | 01/01/2017 |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Directeur/Membre du Conseil | - |
Anciens postes connus de Klaus Breiner
| Sociétés | Poste | Fin |
|---|---|---|
Cervelo Pharmaceuticals Ltd.
 Cervelo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cervelo Pharmaceuticals Ltd. engages in the preparation of pharmaceuticals. It develops drug product candidates for neuropathic, inflammatory, and neurodegenerative diseases. The company was founded by Anthony J. Giovinazzo in 2006 and is headquartered in Mississauga, Canada. | Directeur/Membre du Conseil | 15/12/2009 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Directeur/Membre du Conseil | - |
| ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Klaus Breiner
| The University of North Carolina at Charlotte | Graduate Degree |
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| University of Hagen | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Pevion Biotech AG
 Pevion Biotech AG Pharmaceuticals: MajorHealth Technology Pevion Biotech AG develops efficient and safe vaccines based on proprietary technology. The firm provides preclinical and clinical development of prophylactic/therapeutic vaccines based on its virosome-based technology platform. The company was founded in 2002 and is headquartered in Ittigen, Switzerland. | Health Technology |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Finance |
Cervelo Pharmaceuticals Ltd.
Cervelo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cervelo Pharmaceuticals Ltd. engages in the preparation of pharmaceuticals. It develops drug product candidates for neuropathic, inflammatory, and neurodegenerative diseases. The company was founded by Anthony J. Giovinazzo in 2006 and is headquartered in Mississauga, Canada. | Health Technology |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
Orthocon, Inc.
Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Health Technology |
Natural Dental Implants AG
Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | Health Technology |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Health Technology |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Finance |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Health Technology |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |